Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

The makers of lorvotuzumab mertansine (IMGN901) have halted a clinical trial investigating the use of the drug in extensive-stage small-cell lung cancer (SCLC). An independent monitoring group recommended ending the trial because patients treated with IMGN901 in addition to the chemotherapy agents etoposide (Etopophos) and carboplatin (Paraplatin) fared no better than patients treated with Etopophos and Paraplatin only. Furthermore, the patient group receiving IMGN901 appeared to have higher rates of infections and infection-related deaths, with at least one death potentially related to IMGN901.

Cancer Commons's insight:

Yahoo! Finance | Nov 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Infections Present Significant Risk to Lung Cancer Patients

Lung cancer patients are at high risk of infections stemming from the cancer itself, invasive diagnosis or treatment procedures, or medication side effects such as immune system suppression or tissue damage. Infection symptoms in lung cancer patients may be subtle due to their weakened immune systems and can be difficult to distinguish from noninfectious cancer complications. Lung cancer patients and their care providers therefore need to be extremely vigilant in order to detect dangerous infections early and start treatment right away.


Primary source: http://www.europeanreview.org/wp/wp-content/uploads/8-18.pdf

Cancer Commons's insight:

European Review for Medical and Pharmacological Sciences | Jan 2013

more...
No comment yet.